Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 20/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 10/20 | 1.00 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4891283 | 0.96 | PTGS2 (0.93) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL13575819 | 0.91 | PTGS2 (0.83) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL23965413 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL4893623 | 0.89 | PTGS2 (0.79) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL14163961 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL29366203 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL29402456 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL30988052 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| Etoricoxib SCHEMBL4680 | 0.84 | PTGS2 (1.00) | PTGS2PTGS1ABCC4ABCB11PDE4D | |
| SCHEMBL5210195 | 0.83 | PTGS2 (0.82) | PTGS2PTGS1ABCC4ABCB11PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004199-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2005-01-06 | — | — | US | claimed |
| EP-1349548-A4 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | MERCK & CO INC (US) | 2004-06-02 | — | — | EP | claimed |
| US-20040053968-A1 | Methods and compositions for treating peridontal disease | HARTMAN GEORGE D (US) | 2004-03-18 | — | — | US | claimed |
| US-20040029921-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. | 2004-02-12 | — | — | US | claimed |
| EP-1349548-A2 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | Merck & Co., Inc. (US) | 2003-10-08 | — | — | EP | claimed |
| EP-1322311-A1 | TREATMENT OF INFLAMMATION WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND AN INTEGRIN ALPHA-V ANTAGONIST | Merck & Co., Inc. (US) | 2003-07-02 | — | — | EP | claimed |
| US-20030065011-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | MERCK FROSST CANADA & CO. | 2003-04-03 | — | — | US | claimed |
| WO-2002053099-A2 | METHODS AND COMPOSITIONS FOR TREATING PERIODONTAL DISEASE | MERCK & CO., INC. (US) | 2002-07-11 | — | — | WO | claimed |
| US-20020042375-A1 | Method of treating cancer | HEIMBROOK DAVID C (US) | 2002-04-11 | — | — | US | claimed |
| US-20020040039-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | HARTMAN GEORGE (US) | 2002-04-04 | — | — | US | claimed |
| WO-2002022124-A1 | TREATMENT OF INFLAMMATION WITH A COMBINATION OF A CYCLOOXYGENASE-2 INHIBITOR AND AN INTEGRIN ALPHA-V ANTAGONIST | MERCK & CO., INC. (US) | 2002-03-21 | — | — | WO | claimed |
| EP-0912518-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-05-06 | — | — | EP | claimed |
| US-5861419-A | ANTIINFLAMMATORY AGENTS; ANTIPYRETICS, ANALGESICS; ETORICOXIB PATENT | MERCK FROSST CANAD, INC. (CA) | 1999-01-19 | — | — | US | claimed |
| WO-1998003484-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-01-29 | — | — | WO | claimed |
| US-11858909-B2 | Deuterated etoricoxib, methods of manufacture, and use thereof | Tremeau Pharmaceuticals, Inc. (US) | 2024-01-02 | — | — | US | disclosed |
| US-20080293679-A1 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | CARDAX PHARMACEUTICALS, INC. | 2008-11-27 | — | — | US | disclosed |
| US-7265134-B2 | Tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2007-09-04 | — | — | US | disclosed |
| EP-0912518-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1999-05-06 | — | — | EP | disclosed |
| US-5861419-A | ANTIINFLAMMATORY AGENTS; ANTIPYRETICS, ANALGESICS; ETORICOXIB PATENT | MERCK FROSST CANAD, INC. (CA) | 1999-01-19 | — | — | US | disclosed |
| WO-1998003484-A1 | SUBSTITUTED PYRIDINES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042375-A1 | Method of treating cancer | ACP3, KLK3, FOLH1 | PTGS2 14/4885PTGS1 20/4885ABCC4 3154/4885 |
| US-20080293679-A1 | Use of carotenoids and/or carotenoid derivatives/analogs for reduction/inhibition of certain negative effects of COX inhibitors | LPL, ALOX12, LCLAT1 | PTGS2 9/4885PTGS1 26/4885ABCC4 1599/4885 |
| US-20030065011-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885ABCC4 1696/4885 |
| US-20020040039-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | ITGAV, ITGA5, ITGA2 | PTGS2 28/4885PTGS1 37/4885ABCC4 1871/4885 |
| US-20050004199-A1 | Treatment of inflammation with a combination of a cyclooxygenase-2 inhibitor and an integrin alpha-v antagonist | ITGAV, ITGA5, ITGB5 | PTGS2 27/4885PTGS1 36/4885ABCC4 2019/4885 |
| US-11858909-B2 | Deuterated etoricoxib, methods of manufacture, and use thereof | PTGES3, CYP3A43, PTGER3 | PTGS2 22/4885PTGS1 12/4885ABCC4 2205/4885 |
| US-20040029921-A1 | Substituted pyridines as selective cyclooxygenase-2 inhibitors | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885ABCC4 1696/4885 |
| US-20040053968-A1 | Methods and compositions for treating peridontal disease | ITGB3, ITGB5, ITGB2 | PTGS2 27/4885PTGS1 45/4885ABCC4 2333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.